Question 1

What is ARA-290?

Accepted Answer

ARA 290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) — a heterodimer of EPOR and βcR (CD131). Unlike EPO itself, ARA 290 does not stimulate erythropoiesis and has no effect on red blood cell production. Instead, it activates tissue-protective and anti-inflammatory pathways. Clinical trials have been conducted for sarcoidosis-related neuropathy, diabetic neuropathy, and chronic pain, with promising results for neuropathic pain reduction and nerve fiber regeneration.

Question 2

How does ARA-290 work?

Accepted Answer

ARA 290 activates the innate repair receptor (EPOR/βcR heterodimer) on tissue-protective cells including macrophages, Schwann cells, and neurons. Receptor activation stimulates JAK2/STAT5, PI3K/Akt, and MAPK/ERK anti-apoptotic and anti-inflammatory pathways without affecting erythropoiesis.

Question 3

What are the research applications of ARA-290?

Accepted Answer

Diabetic Neuropathy

Phase 2 trials showed improved corneal nerve fiber density and neuropathic pain scores.

Sarcoidosis

Reduced inflammation and improved small fiber neuropathy.

Chronic Pain

Anti-inflammatory and nerve-regenerative properties.

Question 4

Is ARA-290 safe for research use?

Accepted Answer

ARA-290 should only be handled by qualified researchers following proper laboratory protocols and safety guidelines.

Question 5

Where can I find research studies on ARA-290?

Accepted Answer

Scientific studies on ARA-290 can be found in peer-reviewed journals through databases like PubMed and Google Scholar.

Question 6

What quality standards should ARA-290 meet for research?

Accepted Answer

Research-grade ARA-290 should meet high purity standards, typically >95% purity, with proper analytical certification and storage requirements.

ARA-290